Is NAMS or NAUT more undervalued in 2026?

CirclFi compares NewAmsterdam Pharma Company N.V (NAMS) and Nautilus Biotechnology, Inc. (NAUT) using 13 institutional-grade valuation models. NAMS has a Quality of Company score of 2.3/10 while NAUT scores 4.3/10.

Which is a better buy — NAMS or NAUT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NAMS and NAUT valuations compare?

NAMS at $35.42 and NAUT at $2.60 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NAMS vs NAUT Valuation Comparison 2026 — Intrinsic Value Analysis

NAMS

Biotechnology

NewAmsterdam Pharma Company N.V

Quality

2.3

out of 10

Value Trap

—

Price

$35.42

Last close

Models

12/13

Active

NAUT

Biotechnology

Nautilus Biotechnology, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$2.60

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	NAMS Fair Value	NAMS Upside	NAUT Fair Value	NAUT Upside
Bayesian DCF	Intrinsic	$7.68	-78.3%	$0.67	-74.3%
Earnings Power Value	Intrinsic	$18.09	-39.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.99	-91.8%	$0.86	-67.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NAMS vs NAUT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NAMS vs NAUT — Which Stock Is More Undervalued?

NAUT scores higher with a 4.3/10 quality rating vs NAMS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NewAmsterdam Pharma Company N.V (NAMS) and Nautilus Biotechnology, Inc. (NAUT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NAMS currently trades at $35.42 with a QOC of 2.3/10, while NAUT trades at $2.60 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).